Topical disposition of two strengths of a 125I-rhEGF jelly in rat skin wounds

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 5, 2004, Pages 193-201

  Duconge, J ^a   Prats, P A ^b   Valenzuela, C ^b   Aguilera, A ^b   Rojas, I ^b   Becquer, M A ^a   Alvarez, D ^a   Estrada, L ^c   Alfonso Ortiz S ^a,e   Hardy Rando, E ^b   Garcia Pulpeiro O ^d   Fernandez Sanchez E ^a  

^a UNIVERSITY OF HAVANA   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c Department of Pharmacy   (Cuba)

^d Research and Development Department   (Cuba)

^e Immunoassay Center Cuba   (Cuba)

Author keywords

125I rhEGF; Jelly; Non linearity; Strength; Topical disposition

Indexed keywords

COLLAGEN; IODINE 125; PROTEIN; RECOMBINANT EPIDERMAL GROWTH FACTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG DISPOSITION; DRUG FORMULATION; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN SYNTHESIS; RAT; SKIN DEFECT; SKIN INJURY; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; EPIDERMAL GROWTH FACTOR; GELS; HUMANS; IODINE RADIOISOTOPES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; WOUNDS, PENETRATING;

EID: 4043130310     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.393     Document Type: Article

References (18)

1. Jeschke MG, Herndon DN, Baer W, Barrow RE, Jauch KW. Possibilities of non-viral gene transfer to improve cutaneous wound healing. Curr Gene Ther 2001; 3: 267-278.
2. Jeschke MG, Richter G, Hofstadter F, Herndon DN, Perez-Polo JR, Jauch KW. Non-viral liposomal keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors. Gene Ther 2002; 16: 1065-1074.
3. Deodato B, Arsic N, Zentilin L, et al. Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Ther 2002; 12: 777-785.
4. Wright JB, Lam K, Buret AG, Olson ME, Burrell RE. Early healing events in a porcine model of contaminated wounds: effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen 2002; 3: 141-151.
5. Knauer DJ, Wiley HS, Cunningham DD. Relationship between epidermal growth factor receptor occupancy and mitogenic response. Quantitative analysis using a steady state model system. J Biol Chem 1984; 259: 5623-5631.
6. Carpenter G. Continuous epidermal growth factor delivery in corneal epithelial wound healing. Invest Ophthalmol Vis Sci 1993; 34: 3593-3600.
7. 125I-rhEGF after topical administration to skin wounds. Biopharm Drug Disp 2002; 23: 67-76.
8. Estévez T, Aguilera A, Saez A, Hardy E. Diseño y validación de una celda de difusión para estudios de liberación in vitro de biomoleculas. Biotecnología Aplicada 2000; 17: 187-190.
9. Meier J, Nuesch E, Schmidt R. Pharmacokinetic criteria for the evaluation of retard formulations. Eur J Clin Pharmacol 1974; 7: 429-432.
10. Jijon AJ, Gallup DG, Behzadian MA, Metheny WP. Assessment of epidermal growth factor in the healing process of clean full-thickness skin wounds. Am J Obstet Gynecol 1989; 161: 1658-1662.
11. Celebi N, Erden N, Gonul B, Koz M. Effects of epidermal growth factor dosage forms on dermal wound strength in mice. J Pharm Pharmacol 1994; 46: 386-387.
12. Gonul B, Soylemezoglu T, Babul A, Celebi N. Effects of epidermal growth factor dosage forms on mice full-thickness skin wound zinc levels and relation to wound strength. J Pharm Pharmacol 1998; 50: 641-644.
13. Kuo BS, Kusmik WF, Poole JC, Elsea SH, Chang J, Hwang KK. Pharmacokinetic evaluation of two epidermal growth factors (hEGF51 and hEGF53) in rats. Drug Metabol Dispos 1992; 20: 23-30.
14. Kato Y, Kato M, Ke-Xiu L, Sugiyama Y. Kinetic and biochemical analysis of receptor-mediated endocytosis: influence of receptor up- and down-regulation on the clearance and the pharmacological effects of cytokines. In: 3rd International Symposium on Measurement and Kinetic of in vivo Drug Effects, Danhof M, Steimer JL, Breimer DD. (eds). Leiden/Amsterdam Center for Drug Research (LACDR)-Gorlaeus & Sylvius Laboratories: Noordwijkerhout, The Netherlands, 25-28.
15. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of EPO in rats. J Pharm Exp Ther 1997; 283: 520-527.
16. Liu KX, Kato Y, Kato M, Kaku T, Nakamura T, Sugiyama Y. Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. Am J Physiol 1997; 273: E891-E897.
17. Talmadge JE. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 1998; 33: 241-252.
18. Shah VP, Flynn GL, Yacobi A, et al. Bioequivalence of topical dermatological dosage forms - methods of evaluation of bioequivalence. AAPS/FDA Workshop on 'Bioequivalence of Topical Dermatological Dosage Forms - Methods of Evaluating Bioequivalence', September 4-6, 1996, Bethesda, MD. Skin Pharmacol Appl Skin Physiol 1998; 11: 117-124.